ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2118

Lower Socioeconomic Status at Disease Onset Is Associated with Higher Health Care Costs in Patients with Systemic Lupus Erythematosus: A General Population-Based Cohort Study

Natalie McCormick1, Mohsen Sadatsafavi2, Wenjia Chen3, Carlo A. Marra4 and J. Antonio Avina-Zubieta5, 1Faculty of Pharmaceutical Sciences, University of British Columbia/Arthritis Research Centre of Canada, Vancouver, BC, Canada, 2Division of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada, 3Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, 4Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, 5Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Health care cost, population studies, socio-economic inequities, socioeconomic status and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Health Services Research

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Low socioeconomic status (SES) negatively impacts health outcomes in the general population, as well as in systemic lupus erythematosus (SLE), but the impact on healthcare costs is unknown. In addition, there are little data on the long term costs of SLE cases beginning from diagnosis. To address these knowledge gaps, we examined the relationship between SES at diagnosis, and direct medical costs for 10 years following, in a general population-based context.

Methods:

Data Source: Our administrative data captured all provincially-funded outpatient encounters and hospitalizations (1990-2010), and all dispensed medications (1996-2010) regardless of funding source, in British Columbia, Canada. Sample: We assembled a population-based cohort of all incident cases of SLE who received care from 1996-2010, based on the following validated algorithm: a) two ICD-9-CM codes for SLE at least 2 months apart but within a 2 year period by a non-rheumatologist physician; or b) one ICD code by a rheumatologist or hospitalization. Statistics Canada neighborhood income quintile data for the year of SLE diagnosis was used to define SES. Cost Calculation: Costs for outpatient services and prescriptions were summed directly from billing data. Case-mix methodology was used for hospitalizations. Statistical Analysis: While most cases (87%) had less than 10 years follow-up, estimating long-term costs exclusively from cases with complete follow-up can introduce survival bias, and underestimate costs. Thus, costs were predicted using data from all cases. To account for censoring, follow-up was divided into 90-day periods, and costs per-period were weighted by the person-specific inverse probability of being alive in each period. A generalized linear model was used to predict the cumulative 10-year costs (adjusted for censoring) for cases in each SES group. Parametric bootstrapping was used to obtain 95% confidence intervals (CI). Costs are reported in 2010 Canadian dollars.

Results:

We identified 4,209 incident SLE cases (86% female, mean age 49 years) contributing 18,028 person-years. The 10-year costs from all cases totaled $132,762,777 with 30% from outpatient, 41% from hospitalizations and 30% from medications.

After adjusting for sex, age and baseline Charlson’s comorbidity index, predicted costs were significantly greater (21%, p=0.01) for the lowest SES cases compared to the highest, and averaged $12,489 more per-patient over 10 years.

Hospitalization costs over 10 years were 64% greater for the lowest-SES cases versus the highest ($13,097 vs. $8,001, p=0.05), with most hospitalizations (85%) occurring within 12 months of SLE diagnosis. Medication costs were 18% greater for the lowest SES than the highest, but unlike hospitalization costs, these costs continued over time.

Conclusion:

Lower SES at SLE diagnosis is associated with higher healthcare costs, with medication costs driving this disparity over the long term.

Socioeconomic Quintile

at Diagnosis

N Cases

N Female (%)

Mean Age at Diagnosis (SD)

Median Baseline Charlson Comorbidity Score (IQR)

N Months of

Follow-Up

N

90-Day Costing Periods

N

Ever-Hospitalized (%)

Unadjusted

Overall Costs

Covariate-Adjusted

Mean

Per-Person Predicted Costs

(95% CI)

Overall

Outpatient

Hospital

Medication

All

4,209

3,630 (86%)

49.4 (15.8)

0 (1)

216,339

72,113

2,062

(49%)

$67,847

–

–

–

–

1=Lowest

928

790

(85%)

49.5 (16.5)

0 (1)

46,788

15,596

510

(55%)

$77,895

$72,688

($67,250 – $78,127)

$18,789

($17,467 – $20,111)

$13,097

($9,910 – $16,285)

$24,244

($22,670 – $25,817)

2

834

722

(87%)

49.0 (15.9)

0 (1)

41,976

13,992

422

(51%)

$70,331

$70,837

($64,857 – $76,817)

$20,937

($19,244 – $22,629)

$8,977

($7,445 – $10,509)

$21,662

($20,143 – $23,181)

3=Middle

859

746

(87%)

49.2 (15.4)

0 (1)

44,502

14,834

402

(47%)

$64,872

$67,545

($54,500 – $80,591)

$18,417

($17,044 – $19,790)

$9,501

($6,900 – $12,102)

$22,288

($20,954 – $23,623)

4

811

703

(87%)

49.1 (15.3)

0 (1)

42,135

14,045

382

(47%)

$63,692

$62,088

($56,680 – $67,495)

$18,530

($17,679 – $19,380)

$9,260

($7,102 – $11,418)

$21,985

($20,517 – $23,453)

5=Highest

777

669

(86%)

50.5 (15.8)

0 (1)

40,938

13,646

346

(45%)

$61,741

$60,200

($56,074 – $64,325)

$18,239

($17,032 – $19,447)

$8,001

($6,531 – $9,470)

$20,588

($19,391 – $21,785)


Disclosure:

N. McCormick,
None;

M. Sadatsafavi,
None;

W. Chen,
None;

C. A. Marra,
None;

J. A. Avina-Zubieta,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lower-socioeconomic-status-at-disease-onset-is-associated-with-higher-health-care-costs-in-patients-with-systemic-lupus-erythematosus-a-general-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.